pipeline – XENOTHERA

XENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications

October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

Related Posts

XENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation